Taiwan-headquartered Bora Pharmaceuticals, a global leader in pharmaceutical manufacturing, and British pharma firm GSK have signed a strategic agreement to renew a five-year manufacturing partnership.
Bora purchased the Mississauga facility from GSK in 2020. This renewed collaboration reinforces the long-standing relationship between the two companies and expands the partnership, allowing GSK access to multiple sites within the Bora network, including its newest oral solid dose (OSD) site in Maple Grove, Minnesota.
GSK is the largest pharmaceutical partner operating at Bora’s state-of-the-art Mississauga facility, where Bora provides end-to-end manufacturing services for more than 20 commercial product lines and over 335 individual products. These medicines address specific indications spanning HIV, malaria, pneumonia, parasitic infections, depression, migraine, acne, eczema, and psoriasis. GSK will continue to leverage Bora’s experienced development teams and global commercial manufacturing infrastructure to ensure uninterrupted supply of these critical therapies to patients worldwide.
Since joining the Bora network in 2020, the Mississauga facility has expanded its technical capabilities and customer base, becoming a strategic manufacturing partner for leading global pharmaceutical companies. Targeted investments in flexible manufacturing technologies have enabled the site to support 32 total clients, advance 61 products, and complete more than 400 project and development batches, reinforcing its role in delivering quality, cGMP manufacturing for drug programmes worldwide.
